Not Just Skin Deep: The Cutaneous Lupus Erythematosus Story Dermatologists Need to Know

Scott Elman, MD and Joseph F. Merola, MD emphasized that cutaneous lupus erythematosus (CLE) should not be viewed simply as “systemic lupus of the skin,” as many CLE subtypes have distinct pathogenesis, clinical courses, and treatment needs. They reviewed the major CLE subtypes—acute (ACLE), subacute (SCLE), and chronic (CCLE), including discoid lupus and lupus profundus—and highlighted the wide variability in systemic lupus overlap, ranging from more than 90% in ACLE to approximately 5% in localized discoid disease. Despite this heterogeneity, CLE carries a profound disease burden, with quality-of-life impairment comparable to or worse than major systemic medical conditions.

The presenters stressed the importance of structured monitoring to detect evolving systemic disease, introducing the practical “LABS FOR SLE” mnemonic to guide routine evaluation. Treatment was framed as a rapidly evolving ladder, moving well beyond antimalarials alone. While methotrexate and mycophenolate remain important second-line options, newer targeted therapies are reshaping CLE management. Anifrolumab has demonstrated sustained improvements in skin disease by blocking type I interferon signaling, while emerging agents such as litifilimab, deucravacitinib, and enpatoran offer promising, more precise immune modulation with encouraging skin-specific outcomes.

The session concluded with a call for strategic, multidisciplinary care. Treatment selection should be guided by comorbidities, systemic involvement, and patient-specific goals, with close collaboration between dermatology and rheumatology to address both systemic risk and skin-driven morbidity such as scarring and dyspigmentation. Drs Elman and Merola reinforced that with growing therapeutic options and better disease understanding, dermatologists are uniquely positioned to lead the comprehensive care of patients with CLE.